BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36416959)

  • 1. FGFR2-amplified tumor clones are markedly heterogeneously distributed in carcinomas of the upper gastrointestinal tract.
    Albin J; Fahrig L; Siemanowski J; Rehkaemper J; Gebauer F; Zander T; Buettner R; Bruns CJ; Schroeder W; Alakus H; Hieggelke L; Quaas A
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5289-5300. PubMed ID: 36416959
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
    Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients.
    Kuboki Y; Schatz CA; Koechert K; Schubert S; Feng J; Wittemer-Rump S; Ziegelbauer K; Krahn T; Nagatsuma AK; Ochiai A
    Gastric Cancer; 2018 May; 21(3):401-412. PubMed ID: 28852882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas.
    Rehkaemper J; Korenkov M; Quaas A; Rueschoff J; Pamuk A; Zander T; Hillmer AM; Buettner R; Hoelscher AH; Bruns CJ; Loeser H; Alakus H; Schoemig-Markiefka B
    BMC Cancer; 2020 Jun; 20(1):587. PubMed ID: 32571252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma.
    Tokunaga R; Imamura Y; Nakamura K; Ishimoto T; Nakagawa S; Miyake K; Nakaji Y; Tsuda Y; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Saeki H; Yoshida N; Oki E; Watanabe M; Oda Y; Bass AJ; Maehara Y; Baba H
    Oncotarget; 2016 Apr; 7(15):19748-61. PubMed ID: 26933914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry.
    Park YS; Na YS; Ryu MH; Lee CW; Park HJ; Lee JK; Park SR; Ryoo BY; Kang YK
    Am J Clin Pathol; 2015 Jun; 143(6):865-72. PubMed ID: 25972329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization.
    Tajiri R; Ooi A; Fujimura T; Dobashi Y; Oyama T; Nakamura R; Ikeda H
    Hum Pathol; 2014 Apr; 45(4):725-34. PubMed ID: 24491355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.
    Salem ME; Puccini A; Xiu J; Raghavan D; Lenz HJ; Korn WM; Shields AF; Philip PA; Marshall JL; Goldberg RM
    Oncologist; 2018 Nov; 23(11):1319-1327. PubMed ID: 29866946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
    Van Cutsem E; Bang YJ; Mansoor W; Petty RD; Chao Y; Cunningham D; Ferry DR; Smith NR; Frewer P; Ratnayake J; Stockman PK; Kilgour E; Landers D
    Ann Oncol; 2017 Jun; 28(6):1316-1324. PubMed ID: 29177434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR1 Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal Carcinoma.
    von Loga K; Kohlhaussen J; Burkhardt L; Simon R; Steurer S; Burdak-Rothkamm S; Jacobsen F; Sauter G; Krech T
    PLoS One; 2015; 10(11):e0141867. PubMed ID: 26555375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival.
    Ahn S; Lee J; Hong M; Kim ST; Park SH; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Jung SH; Kang WK; Kim KM
    Mod Pathol; 2016 Sep; 29(9):1095-103. PubMed ID: 27230412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study.
    Su X; Zhan P; Gavine PR; Morgan S; Womack C; Ni X; Shen D; Bang YJ; Im SA; Ho Kim W; Jung EJ; Grabsch HI; Kilgour E
    Br J Cancer; 2014 Feb; 110(4):967-75. PubMed ID: 24457912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR2 gene amplification and clinicopathological features in gastric cancer.
    Matsumoto K; Arao T; Hamaguchi T; Shimada Y; Kato K; Oda I; Taniguchi H; Koizumi F; Yanagihara K; Sasaki H; Nishio K; Yamada Y
    Br J Cancer; 2012 Feb; 106(4):727-32. PubMed ID: 22240789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma.
    Yoon HH; Shi Q; Sukov WR; Lewis MA; Sattler CA; Wiktor AE; Wu TT; Diasio RB; Jenkins RB; Sinicrope FA
    J Clin Oncol; 2012 Nov; 30(32):3932-8. PubMed ID: 22987085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers.
    Hur JY; Chao J; Kim K; Kim ST; Kim KM; Klempner SJ; Lee J
    Pathol Res Pract; 2020 Apr; 216(4):152878. PubMed ID: 32089408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer.
    Minashi K; Yamada T; Hosaka H; Amagai K; Shimizu Y; Kiyozaki H; Sato M; Soeda A; Endo S; Ishida H; Kamoshida T; Sakai Y; Shitara K
    Jpn J Clin Oncol; 2021 Oct; 51(10):1523-1533. PubMed ID: 34258618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer.
    Han N; Kim MA; Lee HS; Kim WH
    Pathobiology; 2015; 82(6):269-79. PubMed ID: 26516773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Tumor DNA Analysis Detects
    Jogo T; Nakamura Y; Shitara K; Bando H; Yasui H; Esaki T; Terazawa T; Satoh T; Shinozaki E; Nishina T; Sunakawa Y; Komatsu Y; Hara H; Oki E; Matsuhashi N; Ohta T; Kato T; Ohtsubo K; Kawakami T; Okano N; Yamamoto Y; Yamada T; Tsuji A; Odegaard JI; Taniguchi H; Doi T; Fujii S; Yoshino T
    Clin Cancer Res; 2021 Oct; 27(20):5619-5627. PubMed ID: 34376535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas.
    Cho EY; Park K; Do I; Cho J; Kim J; Lee J; Kim S; Kim KM; Sohn TS; Kang WK; Kim S
    Mod Pathol; 2013 May; 26(5):677-84. PubMed ID: 23238628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.